- Home
- NAT vs TYRA Comparison
NAT vs TYRA Comparison
Compare NAT & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAT
- TYRA
- Stock Information
- Founded
- NAT 1995
- TYRA 2018
- Country
- NAT Bermuda
- TYRA United States
- Employees
- NAT N/A
- TYRA N/A
- Industry
- NAT Marine Transportation
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- NAT Consumer Discretionary
- TYRA Health Care
- Exchange
- NAT Nasdaq
- TYRA Nasdaq
- Market Cap
- NAT 669.1M
- TYRA 681.7M
- IPO Year
- NAT 1997
- TYRA 2021
- Fundamental
- Price
- NAT $3.54
- TYRA $14.98
- Analyst Decision
- NAT Hold
- TYRA Strong Buy
- Analyst Count
- NAT 1
- TYRA 7
- Target Price
- NAT $3.00
- TYRA $30.71
- AVG Volume (30 Days)
- NAT 3.0M
- TYRA 162.7K
- Earning Date
- NAT 11-28-2025
- TYRA 11-06-2025
- Dividend Yield
- NAT 9.77%
- TYRA N/A
- EPS Growth
- NAT N/A
- TYRA N/A
- EPS
- NAT 0.06
- TYRA N/A
- Revenue
- NAT $301,169,000.00
- TYRA N/A
- Revenue This Year
- NAT N/A
- TYRA N/A
- Revenue Next Year
- NAT $38.51
- TYRA N/A
- P/E Ratio
- NAT $56.98
- TYRA N/A
- Revenue Growth
- NAT N/A
- TYRA N/A
- 52 Week Low
- NAT $2.13
- TYRA $6.42
- 52 Week High
- NAT $3.60
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- NAT 65.83
- TYRA 63.79
- Support Level
- NAT $3.10
- TYRA $14.28
- Resistance Level
- NAT $3.35
- TYRA $15.60
- Average True Range (ATR)
- NAT 0.11
- TYRA 0.70
- MACD
- NAT 0.02
- TYRA 0.08
- Stochastic Oscillator
- NAT 88.78
- TYRA 76.34
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.